Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
Somatic mutations in certain tyrosine kinases have emerged as central 'drivers' of specific
cancers and these mutant proteins are proving to be excellent substrates for targeted …
cancers and these mutant proteins are proving to be excellent substrates for targeted …
[HTML][HTML] EGFR-mutated lung cancer: a paradigm of molecular oncology
The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung
cancer and the subsequent discovery of activating EGFR mutations have led to an explosion …
cancer and the subsequent discovery of activating EGFR mutations have led to an explosion …
[HTML][HTML] Epidermal growth factor receptor mutations in lung adenocarcinoma
MD Siegelin, AC Borczuk - Laboratory investigation, 2014 - Elsevier
Despite tremendous progress in the last decade, lung adenocarcinoma still represents a
tumor with unfavorable prognosis when detected at advanced clinical stage. High-stage …
tumor with unfavorable prognosis when detected at advanced clinical stage. High-stage …
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
R Rosell, AF Cardona, O Arrieta, A Aguilar… - British Journal of …, 2021 - nature.com
Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are a frequent
class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial …
class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial …
Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors
DA Haber, DW Bell, R Sordella… - Cold Spring Harbor …, 2005 - symposium.cshlp.org
Somatic mutations within the kinase domain of the epidermal growth factor receptor (EGFR)
are present in approximately10% of non-small-cell lung cancer (NSCLC), with an increased …
are present in approximately10% of non-small-cell lung cancer (NSCLC), with an increased …
Targeting the epidermal growth factor receptor in EGFR-mutated lung cancer: current and emerging therapies
K Khaddour, S Jonna, A Deneka, JD Patel… - Cancers, 2021 - mdpi.com
Simple Summary Epidermal growth factor receptor (EGFR) mutations occur in a significant
number of lung cancer patients. Treatment outcomes in this subset of patients has greatly …
number of lung cancer patients. Treatment outcomes in this subset of patients has greatly …
EGFR mutations and the terminal respiratory unit
Y Yatabe - Cancer and Metastasis Reviews, 2010 - Springer
Considerable knowledge has accumulated about mutations of the epidermal growth factor
receptor (EGFR)-tyrosine kinase domain since these were first identified in 2004. Patients …
receptor (EGFR)-tyrosine kinase domain since these were first identified in 2004. Patients …
Overcoming therapy resistance in EGFR-mutant lung cancer
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
[HTML][HTML] Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase …
DB Costa - Translational lung cancer research, 2016 - ncbi.nlm.nih.gov
The most frequent epidermal growth factor receptor (EGFR) mutations found by traditional or
comprehensive molecular profiling of lung adenocarcinomas include indels of exon 19 (the …
comprehensive molecular profiling of lung adenocarcinomas include indels of exon 19 (the …
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
J Cadranel, AM Ruppert, M Beau-Faller… - Critical reviews in …, 2013 - Elsevier
Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-
small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine …
small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine …